Cefaclor
Emery Haley, PhD, Scientific Writing Specialist
Cefaclor
Find the Latest FDA-Approved Labelling Information Here: Drugs@FDA Online Database
Administrative Routes
Oral (PO)
Other Names
Ceclor; Ceclor CD
Bacteriostatic or Bactericidal
Bactericidal [1]
Antibiotic Class
Second-Generation Cephalosporin
Mechanisms of Action
Cefaclor, a beta-lactam antibiotic, binds to penicillin-binding proteins (PBPs) on bacterial cell walls. PBPs are essential for the formation of peptidoglycan, which gives the bacterial wall strength and integrity. Binding of cefaclor to PBPs leads to failure of peptidoglycan cell wall synthesis, causing bacterial cell death.
WHO AWaRe Classification
Watch [2]
Empiric Use Recommendations
Yes (alternative for complicated UTI without suspected sepsis) [Infectious Diseases Society of America (IDSA)] [3]
Indication(s) Relevant to UTI
On label for UTI (including cystitis and pyelonephritis) caused by Escherichia coli, Proteus mirabilis, Klebsiella species, and Coagulase-negative Staphylococci.
Checkmarks
CLSI and/or FDA documents support the efficacy of this antibiotic against the following organisms from the Guidance® UTI test: Citrobacter koseri, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, and Proteus mirabilis.
- Ishak, A.; Mazonakis, N.; Spernovasilis, N.; Akinosoglou, K.; Tsioutis, C. Bactericidal versus Bacteriostatic Antibacterials: Clinical Significance, Differences and Synergistic Potential in Clinical Practice. J. Antimicrob. Chemother. 2024, 80, 1–17, doi:10.1093/jac/dkae380
- AWaRe Classification of Antibiotics for Evaluation and Monitoring of Use, 2023 Available online: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04 (accessed on 6 February 2025).
- Complicated Urinary Tract Infections (CUTI): Clinical Guidelines for Treatment and Management Available online: https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/ (accessed on 28 July 2025).
Dr. Emery Haley is a scientific writing specialist with over ten years of experience in translational cell and molecular biology. As both a former laboratory scientist and an experienced science communicator, Dr. Haley is passionate about making complex research clear, approachable, and relevant. Their work has been published in over 10 papers and focuses on bridging the gap between the lab and real-world patient care to help drive better health outcomes.